Roy's source notes point to work by Gomez-Banoy, Cohen and colleagues reviewing cancer care scans taken from 2009 to 2024. The study's GLP-1 link isn't spelled out in the snippet.
Recap by typeshit. Post by Avi Roy on X.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Philstar Life pushes back on how Ozempic gets talked about, framing it as something other than a weight loss drug. Only the headline is available, so tap through for the argument.
Asked whether injectable peptides or supplements are better, the poster says the first step either way is knowing the maker and what the product really contains.
Loading…